【LOOK!】Future XDC Drug Innovation Conference
Future XDC Drug Innovation Conference
On April 17–18, 2025, the Future XDC Drug Innovation Conference convened in Wenjiang, Chengdu, spotlighting two cutting-edge fields: ADCs and RDCs. As a multidisciplinary frontier bridging nuclear technology, medicine, and life sciences, the radiopharmaceutical industry is navigating unprecedented opportunities alongside challenges in technological innovation and cross-sector collaboration.
As a pioneer in the radiopharmaceutical industry, C-RAY collaborates with upstream and downstream partners to strengthen the industrial chain and drive synergistic innovation.
Inauguration Ceremony
Chengdu Medical City Radiopharmaceutical Innovation Ecosystem Alliance
Mr. Qiao Haitao, General Manager of C-RAY, attended the inauguration ceremony as Chairman of the Alliance.
In the evening, C-RAY and QuarkMed co-hosted a networking dinner for representatives across the radiopharmaceutical value chain, fostering dialogue on collaborative innovation to shape the industry’s future.
The alliance aims to drive collaborative innovation across the entire radiopharmaceutical value chain, resolve domestic supply bottlenecks of critical medical isotopes, empower midstream R&D and automated high-quality production, expand downstream clinical applications, and advance industry-wide synergy, collectively paving the way for a thriving future in radiopharmaceuticals.
Booth Highlights
At the exhibition booth, the aroma of coffee blended seamlessly with the enthusiasm of attendees, attracting a steady stream of visitors for consultations and discussions. As a pivotal member of the alliance, C-RAY showcased its comprehensive strengths in radiopharmaceutical CMC , GMP production, and supply chain development.。
Simultaneously, C-RAY actively absorbed cutting-edge concepts and valuable industry insights, which deepened its understanding of sector trends and unlocked fresh perspectives for future innovation.
Successfully Concludes
The RDC Innovation Technology and Supply Chain Forum, chaired by Qiao Haitao, Chairman of the Radiopharmaceutical Innovation Chain Alliance, brought together member companies to explore innovative pathways from research to clinical translation.
Huang Gang, Chairman of the Oceania Nuclear Medicine and Biology Alliance, delivered the opening address, sharing advancements in radiopharmaceutical R&D and nuclear medicine innovation. Zhou Yun, Chief Scientific Officer of United Imaging, and Jan Passchier, Global Laboratory Head of Perceptive, provided expert insights on imaging-driven drug development.
QuarkMed presented its latest achievements in target discovery and indication exploration for radiopharmaceuticals. GoBroad Medical Group inspired attendees with its paradigm-shifting approach to clinical research ecosystems. C-RAY’s General Manager, Qiao Haitao, offered comprehensive solutions for innovative radiopharmaceutical CMC, GMP production, and supply chain development."
During the roundtable discussion, Ms. Chao Heyun, Vice President of Corporate Development at C-RAY, moderated a panel of executives from MesoTopo, Perceptive, GE Healthcare, QuarkMed, GoBroad Medical Group, and United Imaging, who collectively addressed challenges and opportunities across the RDC value chain.
Live Tour + Technical Deep Dive
On April 17 , over 40 experts, corporate leaders, and investors visited C-RAY — the first Class A R&D and manufacturing enterprise in Chengdu Medical City — for an immersive tour of its world-class radiopharmaceutical R&D and production center, established in 2021.
The cGMP-compliant production base, meeting regulatory standards of the U.S. FDA, EU EMA, and China NMPA, houses 13 cGMP-grade radiopharmaceutical production lines. In September 2023, C-RAY obtained a Class A Radiation Safety License approved by China’s Ministry of Ecology and Environment.
The event adopted a ‘Live Tour + Expert Briefing’ format, where over 40 participants were divided into four groups to explore C-RAY’s R&D and production platforms. The tour provided insights into key processes, including:
- Cyclotron production of isotopes (⁶⁴Cu, ¹⁸F, ⁸⁹Zr)
- Automated cleaning of drug packaging materials
- CMC (Chemistry, Manufacturing, and Controls) development
- Non-clinical studies under GLP-like conditions
- Fully automated GMP production.
A highlight of the facility is China’s first fully automated radiopharmaceutical production line with proprietary intellectual property, integrating radiolabeling, sterile filling, labeling, and packaging. Designed to world-class standards, the line employs intelligent automation to address challenges in manual radiopharmaceutical preparation. It utilizes fully automated robotics, vision-based inspection systems, and in-line labeling technologies to achieve end-to-end automation, fully compliant with China GMP and U.S./EU cGMP requirements. The process minimizes occupational radiation exposure risks for personnel. Additionally, the line resolves capacity bottlenecks and enables digital traceability, supporting R&D, clinical trial samples, and commercial batch production. To date, this GMP-compliant line has produced multiple batches of ¹⁷⁷Lu-based novel drugs, accelerating IND submissions and ensuring clinical supply readiness.
Networking Dinner
In the evening, C-RAY and QuarkMed co-hosted a networking dinner for representatives across the radiopharmaceutical value chain, fostering dialogue on collaborative innovation to shape the industry's future.
